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ABSTRACT
Acute lymphoblastic leukemia (ALL) relapse remains a leading cause of cancer 
related death in children, therefore, new therapeutic options are needed. Recently, we 
showed that a peptide derived from Cyclic-AMP Responsive Element Binding Protein 
(CREB) was highly phosphorylated in pediatric leukemias.
In this study, we determined CREB phosphorylation and mRNA levels showing 
that CREB expression was significantly higher in ALL compared to normal bone 
marrow (phosphorylation: P < 0.0001, mRNA: P = 0.004). High CREB and phospho-
CREB expression was correlated with a lower median overall survival in a cohort 
of 140 adult ALL patients. ShRNA mediated knockdown of CREB in ALL cell lines 
blocked leukemic cell growth by inducing cell cycle arrest and apoptosis. Gene 
expression array analysis showed downregulation of CREB target genes regulating 
cell proliferation and glucose metabolism and upregulation of apoptosis inducing 
genes. Similar to CREB knockdown, the CREB inhibitor KG-501 decreased leukemic 
cell viability and induced apoptosis in ALL cell lines, as well as primary T-ALL samples, 
with cases showing high phospho-CREB levels being more sensitive than those with 
lower phospho-CREB levels.
Together, these in vitro findings support an important role for CREB in the survival 
of ALL cells and identify this transcription factor as a potential target for treatment.
INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is the most 
common pediatric malignancy, comprising almost 25% 
of all cancers diagnosed among children [1]. Based on 
immunophenotype, ALL can be classified in two major 
subtypes; B-cell precursor lineage (BCP-ALL) and 
T-cell lineage (T-ALL). The clinical outcome of children 
with ALL remains favorable, with an overall five-year 
event-free survival rate up to 90% [2]. However, relapse 
remains common and cure after relapse is difficult 
to achieve in children [3]. Improvements in outcome 
obtained over the past few decades are largely attributed 
to optimization of combination chemotherapy. However, 
further improvements in outcome appear to be limited by 
chemotherapy related toxicity [4]. Therefore, treatment 
approaches using the new generation of available kinase 
inhibitors targeting leukemia-specific proteins with 
reduced toxicity may further improve conventional 
therapeutic strategies.
Recently, we determined kinase activity profiles in 
primary pediatric ALL, acute myeloid leukemia (AML), 
and chronic phase chronic myeloid leukemia (CML-CP) 
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samples using kinase activity profiling [5, 6]. These results 
revealed significantly elevated phosphorylation of a peptide 
derived from cyclic (c)-AMP responsive element binding 
protein, phosphorylated on tyrosine 134 and serine 133 
(CREB_Y134/S133) in all leukemic samples compared to 
normal bone marrow (NBM). No significant differences in 
CREB_Y134/S133 peptide phosphorylation were observed 
between leukemia subtypes.
The transcription factor CREB acts downstream of 
major signaling pathways, including cAMP-dependent 
protein kinase A (PKA), mitogen-activated protein kinases 
(MAPK) via ribosomal protein S6 kinase (RPS6KA1), and 
phosphatidylinositol 4, 5-bisphosphate 3-kinase (PI3K) / 
Akt [7, 8]. After phosphorylation on serine 133, CREB 
binds to the CREB binding protein (CBP) to regulate 
the transcription of various target genes involved in cell 
proliferation, differentiation and survival [8]. In normal 
hematopoietic cells, previous studies have detected a 
higher CREB expression in progenitor cells (e.g. CD34+ 
cells) compared to differentiated cells [9]. Numerous 
studies have investigated the role of CREB in myeloid 
leukemia [9–12]. Since CREB is frequently expressed 
in bone marrow cells of patients with both myeloid and 
lymphoid acute leukemias and below detectable levels in 
remission samples, it was hypothesized that CREB might 
regulate essential cell functions in these leukemic cells [9, 
10, 13]. Additionally, high CREB expression was found 
to be associated with an increased risk of AML relapse 
[10]. CREB downregulation in myeloid leukemia cell lines 
led to a decrease in cell growth and viability in vitro and 
suppression of leukemia progression followed by a pro-
longed overall survival in a murine imatinib resistant CML 
model [9]. In pediatric AML, it was shown that miR-34b 
promoter hypermethylation causes CREB overexpression 
[11]. Hypermethylation of the miR-34b promoter and 
subsequent higher CREB protein levels were found 
in 66% of the pediatric AML patients [12]. Despite the 
multitude of studies into the role of CREB in myeloid 
leukemias, the relationship between CREB expression 
levels and outcome and the applicability of CREB as a 
potential druggable target in ALL has not been examined.
In this study, we have correlated CREB expression in 
primary ALL patients to outcome. Moreover, we have studied 
the effects of a loss of CREB function on ALL survival and 
gene expression profiles using shRNA mediated knockdown 
of CREB or a CREB inhibitor (KG-501).
RESULTS
High CREB expression in pediatric ALL
Previously, using our kinome profiling set, we 
showed that phosphorylation of a CREB-derived peptide 
containing residue serine 133, a key residue in the 
regulation of CREB mediated gene expression, was among 
the most strongly phosphorylated peptides in the ALL 
samples [6, 24]. Moreover, the CREB_S133 peptide was 
more highly phosphorylated in T-ALL compared to BCP-
ALL (4995.27 and 3904.16, respectively, P = 0.024) [6].
In order to define a role for CREB expression in 
ALL and to compare the expression levels between T-ALL 
and BCP-ALL, we first determined CREB mRNA levels. 
Relative CREB mRNA levels were consistently higher 
in ALL compared to normal bone marrow (P = 0.004, 
Figure 1A). CREB expression levels did not differ between 
BCP-ALL and T-ALL (P = 0.580, Figure 1A).
Phosphorylation levels of CREB_S133 were analyzed 
using phospho-kinase arrays. Overall phosphorylation 
intensities of the 46 protein kinases on the array were 
higher in the pediatric ALL samples compared to the 
normal bone marrow samples (Supplementary Figure 1 and 
Supplementary Table 4). Consistent with earlier reports, 
a prominent difference in phosphorylation intensities 
between normal bone marrow and leukemia samples was 
observed for CREB_S133 phosphorylation (Figure 1B) 
[13]. Normalized CREB_S133 phosphorylation intensities 
showed an 83-fold increase in primary pediatric ALL 
compared to normal bone marrow (mean normalized 
phosphorylation intensities of 2.32 and 0.028, respectively, 
P < 0.0001, Figure 1B). Phosphorylation intensities did 
not differ between T-ALL and BCP-ALL (2.84 and 2.19, 
respectively, P = 0.069, Figure 1B). As expected, we 
observed no correlation between CREB mRNA expression 
levels and CREB_S133 phosphorylation intensities 
(rs = 0.142, P = 0.529).
High CREB expression and phosphorylation is 
associated with reduced overall survival in adult 
primary ALL blasts
As a high CREB expression was found to be 
associated with poor outcome in AML, we investigated the 
relationship between estimated event-free survival rates 
and CREB phosphorylation for 42 pediatric ALL patients. 
Patients were divided into two groups based on CREB 
phosphorylation levels (above and below mean CREB 
phosphorylation intensities). In spite of the small number 
of patients, we observed that patients with high CREB 
phosphorylation levels trended towards a lower event-
free survival relative to patients with low phosphorylation 
levels (P = 0.073, Figure 2).
As we observed a trend in our small pediatric 
cohort, we interrogated a previously described reverse 
phase protein array (RPPA) data set of 140 newly 
diagnosed mostly young adult ALL patients (Figure 
3, Supplementary Table 5A and 5B) [15]. In this 
dataset, normal bone marrow CD34+ cells were used 
as comparison since these cells are known to have high 
CREB expression levels [9]. CREB expression and 
CREB_S133 phosphorylation was found to be above 
that of normal CD34+ cells in 17.1% and 5.0% of the 
ALL patient samples, respectively, while 25.7% (CREB) 
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Figure 1: Normalized CREB expression profiles in pediatric ALL and normal bone marrow (NBM) mononuclear 
cells. CREB mRNA expression levels for normal bone marrow and ALL patients, ALL patients are displayed as a group and distinguished based 
on immunophenotype A. CREB_S133 phosphorylation determined using phospho-kinase arrays for normal bone marrow and ALL patients. ALL 
patients are again shown as one group and distinguished based on immunophenotype B. Asterisks (*) indicate significant differences (P < 0.05) 
of normal bone marrow vs ALL or BCP-ALL vs T-ALL as determined by the Mann-Whitney U test. Horizontal bars indicate median values.
Figure 2: Relationship between CREB phosphorylation and event-free survival in pediatric ALL. Kaplan-Meier plot of 
event-free survival time as function of CREB phosphorylation. The estimated event-free survival time appeared to be lower for patients 
with high CREB phosphorylation intensities (P = 0.073).
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and 66.4% (phospho-CREB_S133) of the primary ALL 
samples showed expression below that of normal bone 
marrow CD34+ cells (Figure 3A and 3B, Supplementary 
Table 5A). To investigate the prognostic value of CREB 
and phospho-CREB expression levels, we examined the 
relationship between overall survival rates and CREB 
expression and phosphorylation. Patients were divided 
into three groups based on expression levels (below 
normal, normal, and above normal protein expression 
levels compared to the 90 interpercentile of normal bone 
marrow CD34+ protein expression levels). Although 
CREB_S133 protein phosphorylation was high in only 
7 patients, both high CREB and phospho-CREB_S133 
levels were found to be associated with a poor outcome 
compared to normal or below normal expression levels 
(Figure 3C and 3D). Patients with high CREB expression 
or phospho-CREB_S133 levels showed a lower median 
overall survival (68 and 33 weeks, respectively) 
compared to patients with normal levels (CREB and 
phospho-CREB_S133 both 198 weeks, P = 0.002 and 
P = 0.001, respectively) or below normal levels (181 
and 182 weeks, P = 0.015 and P < 0.001, respectively, 
Figure 3C and 3D). We conclude from these results that 
high expression or activity of CREB is associated with an 
unfavorable prognosis in ALL.
shRNA-mediated downregulation of CREB 
reduces cell growth and cell viability
Since CREB expression and activity appears to be 
higher in ALL cells compared to normal bone marrow, 
CREB may represent an important signaling protein 
Figure 3: High CREB expression and phosphorylation is associated with reduced overall survival in adult ALL. Box-
plots of CREB A. and phospho-CREB B. protein levels of 140 Ph-negative adult ALL patients distinguished based on immunophenotype. 
Expression levels were normalized using normal CD34+ cells as a comparison because of their known high CREB expression. To determine 
the overall survival, patients were divided into three groups based on CREB C. and phospho-CREB D. expression levels. The proportion 
of surviving patients was lower for patients with high CREB or phospho-CREB expression levels compared to patients with an expression 
at normal CD34+ levels (P = 0.002 and P = 0.001, respectively) or below normal CD34+ levels (P = 0.015 and P < 0.001, respectively)
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both in pediatric and adult ALL. Hence, we investigated 
the role of CREB on leukemic cell survival performing 
shRNA mediated knockdown of CREB in four ALL 
cell lines using three different shRNAs. CREB protein 
expression levels were reduced in all cell lines, albeit 
with variable efficiencies. Despite multiple transductions, 
shCREB1, while highly effective in the other cell lines, 
produced only a minimal reduction in expression (85% 
of shControl cells) in the Molt4 cells. In all other cases, 
a reduction in protein expression levels ≤ 55% of the 
shControl transduced cells was observed (Figure 4, left 
panels). Moreover, we observed that CREB knockdown 
effectively impaired leukemic cell growth in these four 
cell lines ranging from 30% in RS4;11 up to 96% in Jurkat 
and Nalm6 (Figure 4, right panels).
To explain the dramatic effect of CREB knockdown 
on cell growth, we studied the consequences of CREB 
knockdown on cell cycle progression and apoptosis. Cell 
cycle analysis for Jurkat, Nalm6, and RS4;11 revealed that 
CREB knockdown decreased the percentage of cells in 
S and G2/M phases with a concomitant increase of cells in 
the apoptotic sub-G
0
/G1 and / or G0/G1 phases, consistent 
with a cell cycle arrest (Figure 5A). No cell cycle analysis 
was performed on Molt4 transduced cells since this is an 
aneuploid cell line. Complementary to the increase of cells in 
the apoptotic sub-G
0
/G1 phase, Annexin-V staining showed 
an increase in apoptotic cell numbers for the shCREB 
transduced cells at the 144 hour time point as compared 
to the 0 hour time point, which was not observed in cells 
transduced with a scrambled shRNA control (Figure 5B).
Gene expression profiling of CREB 
knockdown cells
Gene expression profiling was performed to 
examine genetic consequences that resulted from shRNA 
Figure 4: CREB is essential for leukemic cell growth and viability. CREB is successfully downregulated in 4 ALL cell lines 
using three different CREB shRNAs. Downregulation was confirmed by Western blot analysis as shown in de left panels. Growth curve 
analysis shows that CREB downregulation results in a decrease in cell growth (right panels). Growth was measured in duplicate by absolute 
cell counts every 48 hours using a Coulter Counter. The results are shown as mean ± standard deviation.
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mediate knockdown of CREB in the four ALL cell lines 
Jurkat, Nalm6, Molt4, and RS4;11 using shCREB2 and 
shCREB3. Since CREB was shown to act either as a 
transcriptional activator (when phosphorylated) or as a 
repressor, we were interested in genes that were either 
up- or downregulated [25]. We identified 1, 022 genes that 
were significantly up- or downregulated in both shCREB2 
and shCREB3 versus shControl transduced cells (P < 0.05, 
Supplementary Table 6). To identify more specific CREB 
target genes within the list of differentially expressed 
genes we correlated differences in gene expression to the 
amount of CREB knockdown. Of the 535 upregulated 
genes, 510 genes were inversely correlated with CREB 
protein expression, and 463 genes were correlated to the 
487 downregulated genes (Pearson’s correlation, P < 
0.05, Supplementary Table 6). The list of downregulated 
genes included putative CREB target genes regulating 
cell proliferation and cell cycle e.g. CIAO2, CSNK1A1, 
MCM10, PAFAH1B1, PSMD5, STAT6, TFDP1, UBE2V1, 
and UBE2V2. Of the known CREB target genes we 
observed upregulation of BAD, BNIP2, and DEDD2, genes 
implicated in the induction of apoptosis.
Interestingly, KEGG pathway analysis identified 
the metabolic pathway involved in glucose metabolism 
as a key effector of CREB knockdown. Multiple 
genes involved in glycolysis e.g. GPI, ALDOC, and 
PKM2, tricarboxylic acid cycle (TCA cycle) e.g. 
DLAT and IDH3A and serine and glycine biosynthesis 
e.g. PHGDH, PSAT1, and SHMT2 were observed in 
the list of downregulated genes (Figure 6). Since it has 
been previously shown that glucose metabolism plays a 
central role in sustaining cancer growth and oncogenic 
transformation [26], the downregulation of essential 
genes involved in this pathway likely contributes to the 
observed phenotypic effects observed in response to 
CREB knockdown.
Decreased ALL cell survival in response to the 
CREB inhibitor KG-501
The effects of pharmacological inhibition on leukemic 
cell survival was evaluated using the CREB inhibitor 
KG-501 in 4 ALL cell lines and 8 primary pediatric ALL 
patient samples. KG-501 restricts the function of CREB 
by inhibiting the CREB/CBP interaction, which requires 
phosphorylation of CREB at serine 133. CREB_S133 
expression levels in the 4 ALL cell lines and 8 primary ALL 
patient samples are shown (Figure 7A). Exposure to KG-
501 induced a dose-dependent decrease in cell viability in 
all cell lines tested, but the LC-50 values for the T-ALL 
cell lines Jurkat (4.1 μM) and Molt4 (3.7 μM) were lower 
than those for the BCP-ALL cell lines Nalm6 (16.7 μM) 
and RS4;11 (>50 μM). This was largely concordant with 
the effects seen after CREB knockdown (Figure 7B). 
Interestingly, RS4;11 cells, which were least affected by 
CREB knockdown and KG-501 treatment, showed the 
Figure 5: CREB downregulation induces cell cycle arrest and apoptosis. Cell cycle analysis shows a reduction in the percentage 
of cells in S and G2/M phases with a concomitant increase of cells in sub-G0 and G0/G1 phases in comparison with shControl A. Annexin-V 
staining shows an increase in apoptotic cell numbers for CREB downregulated cells as compared to control transduced cells B. The results 
are shown as mean ± standard deviation. Asteriks (*) indicate significant differences (P < 0.05) by Student t-test.
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Figure 6: Effect of CREB knockdown on glucose metabolism. Schematic overview of metabolic enzymes involved in glucose 
metabolism affected by shRNA mediated CREB knockdown. Downregulated genes, as determined by gene expression profiling, and their 
role in glucose metabolism are shown in red.
Figure 7: Inhibition of CREB induces cell death in a dose-dependent manner. CREB and phospho-CREB expression was 
determined by Western blot analysis for BCP-ALL and T-ALL cell lines and primary samples A. Effects of the CREB inhibitor KG-501 
were determined after 24 or 48 hours of incubation for primary samples and cell lines, respectively. CREB inhibition results in a dose-
dependent decrease in cell viability as determined by WST-1 conversion. Cell viability percentages were plotted against concentration of 
KG-501 (μM) using four ALL cell lines B., four primary BCP-ALL samples C., and four primary T-ALL samples D.
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lowest phospho-CREB expression levels (Figure 7A). The 
observed decrease in cell viability was inversely correlated 
with the percentage of apoptotic cell numbers (rs = −0.67, 
P = 0.017, Supplementary Figure 2).
Next, the effects of the KG-501 inhibitor were 
evaluated in 8 primary pediatric ALL samples. Whereas 
none of the BCP-ALL samples responded to the drug 
despite high CREB phosphorylation, all 4 primary 
T-ALL samples showed sensitivity to the drug in a dose-
dependent manner (Figure 7C and 7D, LC-50 values 
for T-ALL 1, 2, 3, and 4 were 10.32 μM, 7.16 μM, 9.07 
μM, and 45.90 μM, respectively). The differences in 
sensitivity were reflected by CREB and phospho-CREB 
levels, with primary leukemic T-ALL cells showing high 
CREB expression or activity (T-ALL samples no. 1, 2, and 
3) being more sensitive than those with low CREB and 
phospho-CREB levels (T-ALL sample no. 4) (Figure 7A).
DISCUSSION
Although the survival of children with ALL is 
approaching 90%, ALL relapse remains a leading cause 
of cancer-related death in children [1, 2]. To further 
improve clinical outcome, new therapeutic strategies are 
necessary. To date, the effects of CREB inhibition and 
its role in leukemogenesis have been primarily studied 
in acute myeloid leukemia. Here, we report a prominent 
role for CREB in ALL. Our results show that, relative 
to normal bone marrow, CREB is overexpressed both at 
the mRNA and protein level, consistent with previous 
results of Pigazzi et al, showing high expression of CREB 
in 94% pediatric ALL cases [13]. Additionally, CREB 
has frequently undergone an activating phosphorylation 
on serine 133. No correlation between CREB mRNA 
expression levels and CREB phosphorylation could be 
observed in our study. Since protein phosphorylation is the 
net result of intracellular kinase activity and basal protein 
expression levels (influenced by mRNA translation and 
protein degradation) and the generally poor correlation 
between protein and mRNA concentrations, this may 
not be surprising [27]. Our results demonstrate also that 
high expression and / or phosphorylation of CREB are 
associated with a lower overall survival in an adult ALL 
patient cohort. Furthermore, CREB appears to be essential 
for leukemic cell growth, since both CREB shRNA 
mediated knockdown and pharmacological inhibition 
leads to growth inhibition and cell death.
Studying CREB knockdown using shRNAs in ALL 
cell lines resulted in decreased cell numbers that appeared 
to be net result of changes in cell cycle distribution and 
the induction of apoptosis. We performed gene expression 
profiling to elucidate the phenotypic effects observed in 
response to shRNA mediated CREB knockdown. First of 
all we observed effects of CREB knockdown on CREB 
target genes implicated in cell proliferation, cell cycle, and 
apoptosis, consistent with the observed phenotypic effects. 
Interestingly however, within the list of downregulated 
genes, enzymes involved in glycolysis (GPI, ALDOC, and 
PKM2), TCA cycle (DLAT and IDH3A), and serine and 
glycine biosynthesis (PHGDH, PSAT1, and SHMT2) were 
among the most prominent. Although DLAT and IDH3A 
were previously described as putative CREB target genes, 
all genes were listed as genes with predicted functional 
CREs [28]. The role of CREB in glucose metabolism 
has been extensively studied, especially in the context of 
diabetes mellitus, showing a central role for transducers of 
regulated CREB activity (TORCs, especially TORC2) in 
CREB-dependent gene transcription in response to glucose 
[29, 30]. In cancer cells, an increase in glycolysis, known 
as the Warburg effect, is frequently observed, which allows 
the generation of essential precursors for the synthesis 
of proteins, nucleic acids, and lipids from glycolytic 
intermediates [31, 32]. The observed downregulation 
of these genes in response to shRNA mediated CREB 
knockdown contributes to the strong phenotypic effects 
observed in our cell lines.
In addition to shRNA mediated knockdown, 
we also explored the effects of the CREB inhibitor 
KG-501. We previously showed that cells from normal 
bone marrow are insensitive to the KG-501 inhibitor [14]. 
In accordance with the CREB phosphorylation levels and 
the shRNA results, the cell lines Jurkat, Molt4, Nalm6, 
and 3 / 4 primary T-ALL samples were sensitive to 
CREB inhibition. Unexpectedly, while shRNA mediated 
CREB knockdown and CREB inhibition showed similar 
phenotypic effects in T-ALL cell lines and primary 
T-ALL samples, we observed different phenotypic effects 
between BCP-ALL cell lines and primary samples using 
pharmacological CREB inhibition. Although shRNA 
mediated CREB knockdown, as well as KG-501 showed 
corresponding results in BCP-ALL cell lines, KG-501 
had no effect on the survival of primary BCP-ALL 
samples, despite high CREB phosphorylation levels. 
Although human cancer derived cell lines are the most 
widely used models to test therapeutic strategies, the 
limitations of cell line models are well known [33, 
34]. Additionally, this discrepancy may be explained 
by CREB target gene regulation. Transcription of 
CREB target genes is partly dependent on CREB 
phosphorylation at serine 133 and the subsequent CREB/
CBP interaction. CREB target gene transcription may 
also be induced in a phosphorylation independent manner 
by a family of CREB coactivators, of which TORC 
complexes are the most potent (Supplementary Figure 3) 
[35]. The small molecule antagonist KG-501 restricts 
the function of CREB by inhibiting the CREB/CBP 
interaction in a dose-dependent way (Supplementary 
Figure 3) [36]. Therefore, sensitivity to the CREB/
CBP interaction inhibitor KG-501 appears to be only 
observed when the transcription of CREB target genes is 
predominantly dependent on the CREB/CBP interaction. 
We hypothesize that cells unresponsive to KG-501 
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treatment are able to maintain mediated transcriptional 
regulation by recruiting coactivators that act independent 
of this CREB/CBP interaction.
Moreover, it is also possible that primary T-ALL 
cells are more dependent on CREB relative to BCP-ALL 
cells. The cAMP response element (CRE) has been found 
in the promoters of many T cell-specific genes [37, 38]. 
Furthermore, it has been shown that phosphorylation 
of the proto-oncogene VAV1, downstream of the T 
cell and pre-T cell receptor, activates CREB and that 
in vivo VAV1-deficiencies cause T cell developmental 
defects that resemble CREB-deficiency [39]. Moreover, 
this CREB dependency might be Notch 1 dependent. 
Aberrant activation of the Notch 1 signaling pathway 
is seen in > 60% of the T-ALL cases [40]. Notch 1 is 
able to activate the serine/threonine kinase Akt, which 
acts upstream of CREB, contributing to leukemogenesis 
[41]. Although no direct relationship between Notch 1 
and CREB has been reported in leukemia to date, Notch 
regulates the phosphorylation of CREB involved in long-
term memory formation in Drosophila melanogaster [42]. 
Finally, we cannot rule out that the difference between 
primary T-ALL and BCP-ALL samples reflects KG-501 
off-target effects. Since the presence of the KIX domain 
is required for more transcriptional activities, other 
inhibitory effects of KG-501 on factors that associate with 
the KIX domains, such as NF-kB, have been observed 
[36]. In addition, a recent study describes that KG-501 
also interferes with the interaction between c-Myb and the 
KIX domain of the coactivator p300 in vitro and inhibits 
Myb activity in vivo [43].
In conclusion, we have demonstrated that high 
CREB expression and activity is associated with reduced 
overall survival in ALL. Moreover, our in vitro findings 
suggest an important role for CREB in the survival 
of acute lymphoblastic leukemia cells. These results 
underscore the need for future investigations aimed at 
validating the role of CREB as a potential therapeutic 
target for acute lymphoblastic leukemia.
MATERIALS AND METHODS
Patients
Primary blood and bone marrow samples from 
ALL patients or patients without hematologic disorders 
were collected after getting written informed consent 
in accordance with the regulations and protocols of the 
Medical Ethical Committee of the University Medical 
Center Groningen (UMCG) and the Institutional Review 
Board of the University of Texas M.D. Anderson Cancer 
Center (MDACC). Samples from UMCG were processed 
as previously described [14]. Patients’ characteristics, 
as well as an overview of the selected ALL patients is 
shown (Supplementary Tables 1 and 2, respectively). 
For RPPA analysis we used protein derived from the 
leukemia-enriched fraction of 140 mostly young adult 
ALL patients (79 Philadelphia-negative common-
ALL (CALLA), 42 Philadelphia-negative preB-ALL, 
and 19 T-ALL) [15]. As cytogenetic abnormalities are 
differentially distributed between pediatric and adult 
patients, we excluded the BCR-ABL1 positive leukemias 
and the B-Cell lymphoma population from the adult 
cohort. Patients’ characteristics of adult ALL patients are 
summarized (Supplementary Table 3).
Cell lines
The T-ALL cell lines Jurkat and Molt4 and the BCP-
ALL cell lines Nalm6 and RS4;11 were purchased from the 
American Type Culture Collection (Manassa, VA, USA) 
and cultured in RPMI-1640 or αmem medium (Cambrex 
Bio Science, East Rutherford, NJ, USA) supplemented 
with 10% fetal calf serum (FCS, Bodinco, Alkmaar, The 
Netherlands) and 1% penicillin/streptomycin (Gibco, 
Carlsbad, CA, USA).
RNA isolation and quantitative real-time PCR 
(qRT-PCR)
Total RNA was isolated (RNeasy mini kit, Qiagen, 
Hilden, Germany) and subsequent complementary DNA 
was synthesized from 1 μg RNA (First Strand cDNA 
Synthesis kit, Thermo Scientific, Waltham, MA, USA) 
according to manufactures protocol. CREB mRNA 
expression was detected in triplicate using SYBR Green 
qRT-PCR (Applied Biosystems, Darmstadt, Germany) and 
normalized to RPL22 as a reference gene [16]. Relative 
mRNA expression levels of the gene of interest were 
calculated using the 2–ΔΔCT method relatively to the normal 
bone marrow sample with the highest CREB mRNA 
expression level [17].
Antibody microarrays
Acute lymphoid leukemia patient samples were 
subjected to a human phospho-kinase microarray (Catalog 
Number ARY003, R&D Systems, Minneapolis, MN, 
USA) following manufacturers protocol. Eight of the 42 
arrays (4 T-ALL and 4 BCP-ALL) were published before 
[6]. The experimental procedures and data analysis were 
performed as described earlier [6].
Reverse phase protein array (RPPA)
The methodology, validation, and statistical 
analysis of the RPPA technique are fully described in 
previous publications and are briefly summarized in the 
Supplementary Information [18–23]. Expression was 
compared to the expression of normal CD34+ cells as a well-
defined control with a known high CREB expression. Cases 
were divided into three cohorts, below, above or within the 
90% confidence interval of normal CD34+ cells, respectively.
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shRNA mediated knockdown
Lentiviral vector (pLKO.1) containing shRNA 
sequences targeting CREB were obtained from Open 
Biosystems (Waltham, MA, USA) and genetically modified 
into a pLKO1-mCherry vector. Sequences are available 
upon request. Lentiviral particles were generated by 
co-transfection of pLKO1-mCherry-shCREB or scrambled 
vector with packaging plasmid psPAX2 and the envelope 
plasmid pMD2.G into 293T cells using FuGENE HD 
transfection reagent (Roche, Woerden, The Netherlands). 
Leukemic cells were incubated with lentiviral supernatants 
for one or two consecutive days after which stably 
transduced cells were expanded.
Western blot analysis
Cells from primary blood or bone marrow samples 
from newly diagnosed ALL patients, ALL cell lines, and 
transduced cells were lysed and denaturized in laemmli 
sample buffer (Bio-Rad laboratories, Veenendaal, The 
Netherlands). Western blots were performed as previously 
described [14]. CREB and phospho-CREB antibodies 
were obtained from Cell Signaling (Danvers, MA, USA). 
Loading control was visualized using β-actin (Santa Cruz 
Biotechnology, Dallas, TX, USA) or Ponceau S (Sigma-
Aldrich, Buchs, Switzerland). Signals were digitally 
quantified with subtraction of background (LI-COR 
Biosciences, Lincoln, NE, USA) and normalized using 
the loading control.
Flow cytometric analysis
Apoptosis analysis was conducted by Annexin 
V-FITC/PI or Annexin V-FITC labeling solution 
(Annexin-V-FLUOS Staining Kit, Roche). A propidium 
iodide/Rnase A DNA labeling was performed for cell cycle 
analysis according to standard techniques as described 
in the Supplementary Information. All flow cytometry 
experiments were performed on a LSR-II flow cytometer 
(BD FACS DIVA software, BD bioscience, Breda, The 
Netherlands) and analyzed using FlowJo software (Tree 
Star Inc., Ashland, OR, USA).
Gene expression
Total RNA was isolated from CREB or scrambled 
transduced cells (RNeasy mini kit). The quality control, 
RNA labeling, hybridization, and data extraction was 
profiled on Illumina HumanHT-12 v4.0 Expression 
BeadChips, all performed at ServiceXS B.V. (Leiden, 
The Netherlands). Scans (Illumina iScan), image analysis 
and extraction of raw data (Illumina GenomeStudio 
v2011.1) was done, after which we performed quantile 
normalization and log2-transformation. Gene expression 
data have been deposited in NCBI’s Gene Expression 
Omnibus (GEO) database and are accessible through GEO 
Series accession number GSE68413.
Cell viability assay
In vitro drug sensitivity after KG-501 (Sigma-
Aldrich) exposure was determined with a WST-1 based 
cell viability assay (Roche) as described previously, and 
calculated as percentage of untreated controls [14]. LC50 
values represent drug doses inhibiting cell viability within 
24 or 48 hours.
Statistical analysis
Estimated event-free and overall survival analyses 
were performed using the Kaplan-Meier method in SPSS 
(Version 20, IBM, Armonk, NY, United States). Estimates 
at specific time points are provided with 95% confident 
intervals (CIs). Data was censored at time of an event or 
at the last follow-up visit. The logrank test was applied 
to compare Kaplan-Meier plots between patient groups. 
Experimental data is presented as mean values from in 
general three experiments ± standard deviation (SD), unless 
described differently. Statistical analyses were perfromed 
with The non-parametric Mann-Whitney U test and 
the parametic paired and unpaired two-tailed t-test (SPSS). 
P-values < 0.05 were considered as statistically significant.
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